101 related articles for article (PubMed ID: 4007635)
1. Effect of ticlopidine on neutrophil chemotaxis in rats.
Cohn M; Matzner Y; Eldor A
Haemostasis; 1985; 15(2):114-8. PubMed ID: 4007635
[TBL] [Abstract][Full Text] [Related]
2. Short-term inhibition of ADP-induced platelet aggregation by clopidogrel ameliorates radiation-induced toxicity in rat small intestine.
Wang J; Albertson CM; Zheng H; Fink LM; Herbert JM; Hauer-Jensen M
Thromb Haemost; 2002 Jan; 87(1):122-8. PubMed ID: 11848440
[TBL] [Abstract][Full Text] [Related]
3. Comparison between the antiaggregating effect of ticlopidine in whole blood, platelet-rich plasma and washed platelets of the rat.
Randon J; Lefort J; Vargaftig BB
Thromb Res; 1982 Apr; 26(1):13-20. PubMed ID: 7048623
[TBL] [Abstract][Full Text] [Related]
4. Effects of ticlopidine, a new platelet aggregation inhibitor in man.
Thebault JJ; Blatrix CE; Blanchard JF; Panak EA
Clin Pharmacol Ther; 1975 Oct; 18(4):485-90. PubMed ID: 1100310
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of platelet aggregation by a new agent, Ticlopidine.
Ashida SI; Abiko Y
Thromb Haemost; 1979 Feb; 40(3):542-50. PubMed ID: 425067
[TBL] [Abstract][Full Text] [Related]
6. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
7. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
8. Ticlopidine augments luminol-dependent chemiluminescence in human neutrophils.
Bednar MM; Dooley RH; Tapanes R; Lublin JC; Gross CE
J Biolumin Chemilumin; 1995; 10(2):85-9. PubMed ID: 7676854
[TBL] [Abstract][Full Text] [Related]
9. Platelet aggregation measured in rabbit whole blood: in vitro study of 3 aggregating agents and ex vivo inhibition by aspirin and ticlopidine.
Chevolet C; Grosdent JC; Reiters GM; Dresse A
Arch Int Pharmacodyn Ther; 1982 Oct; 259(2):310-1. PubMed ID: 6817725
[No Abstract] [Full Text] [Related]
10. Ticlopidine activity on platelet function in patients with enhanced platelet aggregation. A short-term crossover study.
Gensini GF; Favilla S; Breschi C; Abbate R; Costanzo G; Neri Serneri GG
Haemostasis; 1983; 13(5):294-300. PubMed ID: 6228500
[TBL] [Abstract][Full Text] [Related]
11. Ticlopidine and platelet function.
Lecompte T; Lecrubier C; Potevin F; Samama M
Thromb Haemost; 1986 Jun; 55(3):437-8. PubMed ID: 3529484
[No Abstract] [Full Text] [Related]
12. Changes of rabbit platelet function on simultaneous administration of ticlopidine hydrochloride and OKY-046.
Kosugi T; Nakamura M; Saitoh S; Kinjoh K
Int J Tissue React; 1991; 13(3):123-9. PubMed ID: 1960013
[TBL] [Abstract][Full Text] [Related]
13. Pharmacodynamics of ticlopidine: relation between dose and time of administration to platelet inhibition.
Kuzniar J; Splawinska B; Malinga K; Mazurek AP; Splawinski J
Int J Clin Pharmacol Ther; 1996 Aug; 34(8):357-61. PubMed ID: 8864800
[TBL] [Abstract][Full Text] [Related]
14. A possible method to control prolongations of bleeding time under antiplatelet therapy with ticlopidine.
Thébault J; Blatrix C; Blanchard J; Panak E
Thromb Haemost; 1982 Aug; 48(1):6-8. PubMed ID: 7135344
[TBL] [Abstract][Full Text] [Related]
15. Mode of action of ticlopidine in inhibition of platelet aggregation in the rat.
Ashida SI; Abiko Y
Thromb Haemost; 1979 Apr; 41(2):436-49. PubMed ID: 224522
[TBL] [Abstract][Full Text] [Related]
16. In vivo study of platelet aggregation in rats.
Pinon JF
J Pharmacol Methods; 1984 Sep; 12(2):79-84. PubMed ID: 6536819
[TBL] [Abstract][Full Text] [Related]
17. The mechanism of inhibitory effect of eicosapentaenoic acid on phagocytic activity and chemotaxis of human neutrophil granulocytes.
Sipka S; Dey I; Buda C; Csongor J; Szegedi G; Farkas T
Clin Immunol Immunopathol; 1996 Jun; 79(3):224-8. PubMed ID: 8635279
[TBL] [Abstract][Full Text] [Related]
18. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
19. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine.
Bastida E; Escolar G; Almirall L; Ordinas A
Thromb Haemost; 1986 Jun; 55(3):333-7. PubMed ID: 3750263
[TBL] [Abstract][Full Text] [Related]
20. Comparative study of platelet aggregation measured with 3 different methods (photometric and impedance) in ticlopidine treated patients.
Lecrubier C; Girard P; Noire P; Samama M
Agents Actions Suppl; 1984; 15():60-7. PubMed ID: 6592946
[No Abstract] [Full Text] [Related]
[Next] [New Search]
